Developing Therapeutics That Teach the Body to Heal Itself
Dr. Wells’ promotion comes as the company’s HIV clinical trial progresses American Gene Technologies, a clinical-stage biotechnology company based in Rockville, Maryland, has promoted Barry H. Wells, M.D. as head of business development....
Beginning the analytic treatment interruption is a pivotal step to potentially demonstrating a gene therapy cure for HIV. American Gene Technologies, a clinical-stage biotechnology company, has reached a turning point in its HIV cure cli...
Dr. Boyle’s biotech and intellectual property expertise strengthen the team as the company proceeds to next phase of its HIV cure clinical trial American Gene Technologies, a clinical-stage biotechnology company, has appointed Jeff Boyle...
AGT welcomes additional support of its HIV Cure clinical trial and broad gene therapy development platform American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, announced today that angel investor Ride W...
Exciting HIV Clinical Trial Update American Gene Technologies’ HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals. “This is a critical step in our mission to cure HIV using gene therapy,” said Am...
HIV Program Treatment Withdrawal Safety and efficacy blood markers have been recorded in the Phase 1 human trial for AGT’s HIV cure. We expect the antiretroviral treatment withdrawal studies to start this quarter. Six patients have recei...
HIV Program Update Five for Five! American Gene Technologies (AGT) announced that it has reached another important milestone in its HIV cure program. Five participants were treated with AGT103-T and are stably engrafted with genetically ...
HIV Program Update Enrolled First Cohort Since our last Newsletter, AGT has enrolled its first cohort of six participants in its Phase 1 study of AGT103-T against HIV. Updates on the RePAIR Clinical Trial (AGT103-T) Clinical Update [RePA...
Subscribe to our YouTube Channel Dr. Conant was the first physician to diagnose HIV in San Francisco while running the inpatient dermatology service at the University of California San Francisco. Before anyone recognized the virus or und...
Subscribe to our YouTube Channel On the heels of Silicon Valley’s branding as one of the world’s largest tech hubs, the BioHealth Capital Region aims to brand the DMV region as one of the most prominent BioHealth clusters in the Mid-Atla...
Subscribe to our YouTube Channel Mantell Associates Network interviews Jeff Galvin, CEO and Founder of American Gene Technologies™ (AGT) for its global Podcast listeners. In this interview, Galvin shares the company’s cell and gene the...
Subscribe to our YouTube Channel Jeff Galvin, CEO of American Gene Technologies, presents AGT’s latest news at the BIO Digital International Convention 2021. As the first patient in AGT’s Phase 1 clinical trial is infused with AGT103-T, ...
Download the Report The exact origins of Human Immunodeficiency Virus (HIV) are not precisely known, but researchers theorize that the virus may have originated in chimpanzees,1and then crossed to humans via blood borne pathway. It is no...
Original post on baltimoresun.com By Giacomo Bologna and Meredith Cohn Baltimore Sun At his State of the Union speech in March, President Joe Biden urged Congress to fund a new federal agency that would “supercharge” breakthrough medic...
Original post on citybiz.co American Gene Technologies, a clinical-stage biotechnology company, has appointed Jeff Boyle, PhD as chief science officer. Dr. Boyle comes to the post with deep biotechnology expertise which will help furth...
Original post on WJLA.com We have an update in what developers hope will be an HIV cure, a story we’ve been following for more than a year now. A Maryland-based company says its early data in three patients shows their altered cells ar...
With almost three years of COVID consuming our lives, a reprieve from viral outbreaks seemed deserved. However, that was not to be. A new virulent pathogen known as monkeypox emerged surprisingly quickly earlier this year. In May 2022, a...
Contributing Author John Vandermosten, Senior Biotechnology Analyst One hundred and fifty years ago, the world of medicine was radically different from today. The pharmaceutical market was dominated by powders, potions, elixirs and cord...
Contributing Author John Vandermosten, Senior Biotechnology Analyst Transaction Trends 2021: Pandora’s Box 2020 was a tremendous year for Initial Public Offerings (IPOs) where 494 new issues came to market[1], but the achievement was ec...
Contributing Author John Vandermosten, Senior Biotechnology Analyst Cell therapy is the transfer of therapeutic cells to a patient. It replaces damaged cells or enhances normal cells with modified new ones.[1] The cells used in the ...
Subscribe to our newsletter to keep up to date with all the latest news about AGT!
